Pear Therapeutics Completes $64M Series C Financing
Summary
Pear Therapeutics closed a $64 million Series C financing led by Temasek with participation from existing and new investors. The company plans to use the capital to expand commercialization of its reSET product suite, advance its clinical pipeline, and pursue additional assets. Pear focuses on prescription digital therapeutics that use software-based disease treatments backed by clinical trials and FDA authorization. The company already has FDA-authorized products and recently completed a commercial launch with Sandoz for reSET. This funding gives Pear more room to scale its product portfolio and grow its market footprint.
Funding
Amount
$64.0M
Total raised
Date
January 4, 2019
Announcement date
Investors
EDBI, Novartis Venture Fund, Arboretum Ventures, 5AM Ventures, Trustbridge Partners
Lead investors
Company
peartherapeutics.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected